Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by donkeyfeatherson Nov 15, 2021 1:18pm
166 Views
Post# 34128005

RE:RE:SVA should be trading at $3.40 minimum

RE:RE:SVA should be trading at $3.40 minimum

Metalsguy1 wrote:
steadfast I have given up on the idea that management actually listens here. They are luke a mule pulling the cart that ignores the whip of investor concerns. I would not even call the current SP a breakout because right now it looks like a failed breakout. Crossing 1.50 should have formed a new string level of support but as I said the volume that got us over that just wasn't good enough and we would drift down. It's the holiday season...the chances of news before year end are dwindling as will that share price will as well. The noobs will continue to chatter with excitement the rest of us have been here long enough to know better. There was a time I would have said 3 or 4 a share was conservative but with the glacial progress... who knows


In 24 months, if no adverse events and conformal coating tests well underway, the leverage will definitely be there to extract $3-4 per share.  The problem that SF and MS and you, know, is the legacy relationship between the board, the business development guy in charge, and the IR gamesmanship that has gone on forever.  

FOMO when something does get announced is real.  So is the trading manipulation by our co-investees.  So is the way the board at the last AGM feathered their bed in anticipation of deals in the future before there is any ink applied to a contract that confirms the company's ability to make real its claims about a cure across populations.  


Turning the science into money.  That is what all of us doubters wonder about.  What I see is some guys who've known one another for a while, closing ranks when we investors question their inability to montetize in ways other than pump&dump.  We, the cash infusers, should not give them another calendar year after the next AGM.  Either they monetize, or we vote to make substantial changes going forward.
DF
 

<< Previous
Bullboard Posts
Next >>